Innosuisse has approved CHF 1.55 million in non-dilutive funding to support cryoWrite’s development into a scalable, commercial product. We are very grateful for this support and look forward to executing the project efficiently. In the meantime, we will continue to supply a limited number of cryoWriters to select labs from our small-scale production facility. It is truly impressive to see the innovative methods researchers have already developed using the few units delivered so far.
Categories
